Skip to main content
SpringerLink
Log in

Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence

  • Systematic Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Background

The last decade has witnessed the increasing use of biologics for the treatment of ankylosing spondylitis (AS). Drug survival is an outcome incorporating real-world effectiveness and safety. However, the drug survival of biologics in treating AS is unclear.

Objective

The aim was to assess the drug survival of biologics (tumor necrosis factor inhibitors and anti-interleukin-17 monoclonal antibodies) in treating AS.

Methods

We conducted a systematic review and meta-analysis and searched the PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase databases up to 13th May 2020. Studies that analyzed the drug survival of biologics for AS and reported the respective annual data for each biologic for at least 1 year were included. Two authors independently screened and selected studies and assessed their risk of bias. A third author was available for arbitrating discrepancies. The Newcastle–Ottawa Scale was employed to evaluate the risk of bias of included studies. We conducted a random-effects model meta-analysis to obtain pooled drug survival from year 1 to 5. We performed subgroup analyses for biologic-naïve patients, first-line versus second- and third-line biologics, discontinuation due to loss of effectiveness and adverse effects, and high-quality studies.

Results

We included 39 studies with 32,493 patients. The drug survival decreased from 76% at year 1 to 51% at year 5 for etanercept, from 75 to 51% for adalimumab, from 76 to 53% for infliximab, from 72 to 49% for golimumab, and from 63 to 57% for certolizumab pegol. The drug survival rate for secukinumab was 0.77 (95% confidence interval 0.64‒0.90) at year 1. Subgroup analyses on biologic-naïve patients and discontinuation due to adverse effects found no differences in the drug survival of various biologics except for a lower drug survival of infliximab in biologic-naïve patients. The drug survival for first-line biologics was higher than for second- and third-line biologics.

Conclusion

To the best of our knowledge, this study is the first systematic review and meta-analysis on the drug survival of biological therapies for AS patients. The drug survival of all biologics in treating AS appeared comparable, but is higher in first-line biologics than second- and third-line biologics. To date there are scarce data on the drug survival of newly available biologics, for example, anti-interleukin-17 biologics.

PROSPERO registration No

CRD42018114204.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dougados M, Baeten D. Spondyloarthritis Lancet. 2011;377(9783):2127–37. https://doi.org/10.1016/s0140-6736(11)60071-8.

    Article  PubMed  Google Scholar 

  2. Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017;7(9):e015872. https://doi.org/10.1136/bmjopen-2017-015872.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73. https://doi.org/10.1136/annrheumdis-2013-203582.

    Article  PubMed  Google Scholar 

  4. Wronski J, Fiedor P. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought? J Clin Pharmacol. 2019;59(4):445–62. https://doi.org/10.1002/jcph.1348.

    Article  CAS  PubMed  Google Scholar 

  5. Arends S, Brouwer E, Efde M, Veer E, Bootsma H, Wink F, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61–8.

    PubMed  Google Scholar 

  6. Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16(1). https://doi.org/10.1186/s12891-015-0620-4.

  7. Heinonen AV, Aaltonen KJ, Joensuu JT, Lähteenmäki JP, Pertovaara MI, Romu MK, et al. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol. 2015;42(12):2339–466. https://doi.org/10.3899/jrheum.150389.

    Article  CAS  PubMed  Google Scholar 

  8. van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–91. https://doi.org/10.1136/annrheumdis-2016-210770.

    Article  PubMed  Google Scholar 

  9. Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020. https://doi.org/10.1080/14712598.2020.1761957.

  10. Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA Study. Adv Ther. 2020. https://doi.org/10.1007/s12325-020-01352-8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613. https://doi.org/10.1002/art.41042.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Datab Syst Rev. 2015(4):Cd005468. https://doi.org/10.1002/14651858.CD005468.pub2.

  13. Yin Y, Wang M, Liu M, Zhou E, Ren T, Chang X, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther. 2020;22(1):111. https://doi.org/10.1186/s13075-020-02208-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Takacs P, Lathia U, Shin J, Nantel F. Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis. Patient Prefer Adherence. 2019;13:157–63. https://doi.org/10.2147/ppa.S186776.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ruwaard J, l’Ami MJ, Marsman AF, Kneepkens EL, van Denderen JC, van der Horst-Bruinsma IE et al. Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. Scand J Rheumatol. 2018;47(2):122–6. https://doi.org/10.1080/03009742.2017.1330419.

  16. Pavelka K, Zavada J, Kristkova Z, Szczukova L. Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in realworld setting of Czech registry attra. Ann Rheum Dis. 2018;77:605–6. https://doi.org/10.1136/annrheumdis-2018-eular.2407.

    Article  Google Scholar 

  17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.

    Article  PubMed  Google Scholar 

  19. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. John Wiley & Sons: 2011. p. 672. Available from: https://market.android.com/details?id=book-NKMg9sMM6GUC.

  20. Yang L, Dong J, Jiang S, Shi W, Xu X, Huang H, et al. Red and processed meat consumption increases risk for non-Hodgkin lymphoma: a PRISMA-compliant meta-analysis of observational studies. Medicine (Baltimore). 2015;94(45):e1729. https://doi.org/10.1097/md.0000000000001729.

    Article  CAS  Google Scholar 

  21. García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P, et al. Reasons for discontinuation and adverse effects of TNFα inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother. 2017;51(5):388–93. https://doi.org/10.1177/1060028016682330.

    Article  CAS  PubMed  Google Scholar 

  22. Acar M, Juneja P, Handel M. Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD). Open Access Rheumatol. 2018;10:151–60. https://doi.org/10.2147/OARRR.S179704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jeong H, Eun YH, Kim IY, Kim H, Ahn JK, Lee J, et al. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea. Korean J Intern Med. 2018;33(2):407–16. https://doi.org/10.3904/kjim.2016.042.

    Article  PubMed  Google Scholar 

  24. Lee JW, Kang JH, Yim YR, Kim JE, Wen L, Lee KE et al. Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. PLoS One. 2015;10(7). https://doi.org/10.1371/journal.pone.0131864.

  25. Park JW, Yoon YI, Lee JH, Park JK, Lee EB, Song YW, et al. Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis. Clin Exp Rheumatol. 2016;34(4):592–9.

    PubMed  Google Scholar 

  26. Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014;29(9):1205–11. https://doi.org/10.3346/jkms.2014.29.9.1205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lie E, Kristensen LE, Forsblad-D'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74(6):970–8. https://doi.org/10.1136/annrheumdis-2014-206616.

    Article  CAS  PubMed  Google Scholar 

  28. Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - A retrospective analysis. Int J Clin Pharmacol Ther. 2012;50(12):867–72. https://doi.org/10.5414/CP201707.

    Article  CAS  PubMed  Google Scholar 

  29. Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, et al. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis. Eur J Health Econ. 2014;15(Suppl 1):S93–S100. https://doi.org/10.1007/s10198-014-0598-0.

    Article  PubMed  Google Scholar 

  30. Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Charland K, et al. Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data. Clin Rheumatol. 2018;37(9):2351–60. https://doi.org/10.1007/s10067-018-4141-z.

    Article  PubMed  Google Scholar 

  31. Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-turmor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Care Res (Hoboken). 2008;59(2):234–40. https://doi.org/10.1002/art.23333.

    Article  CAS  Google Scholar 

  32. Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine. 2010;77(4):325–9. https://doi.org/10.1016/j.jbspin.2010.02.014.

    Article  CAS  PubMed  Google Scholar 

  33. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: Two years' drug survival. Rheumatol Int. 2010;30(12):1611–20. https://doi.org/10.1007/s00296-009-1203-1.

    Article  CAS  PubMed  Google Scholar 

  34. Lindstrom U, Olofsson T, Wedren S, Qirjazo I, Askling J. Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther. 2019;21(1):128. https://doi.org/10.1186/s13075-019-1908-9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Saevarsdottir S, Santacatterina M, Turesson C, Forsblad H, Jacobsson L, Lindblad S. Clinical characteristics and outcome of golimumab treatment differs between bio-naïve and patients previously exposed to biologicals. Nationwide results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA), ankylosing spondylitis (AS) and Other Spondylarthritidies (SPA). Arthritis Rheumatol. 2014;66:S705. https://doi.org/10.1002/art.38914.

  36. Dongen CV, Kneepkens E, Vogelzang E, l'Ami M, Krieckaert C, Van Der Horst I et al. Etanercept retention rates in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2014;73. https://doi.org/10.1136/annrheumdis-2014-eular.5199.

  37. Walsh JA, Adejoro O, Chastek B, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res. 2018;7(4):369–80. https://doi.org/10.2217/cer-2017-0076.

    Article  PubMed  Google Scholar 

  38. Hunter T, Schroeder K, Sandoval D, Deodhar A. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther. 2019;6(2):207–15. https://doi.org/10.1007/s40744-019-0148-4.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Baraliakos X, Poddubnyy D, Behrens F, Curiale C, Tarallo M, Hernandez Daly AC, et al. PBI81 Persistence and healthcare resource use (HCRU) in patients initiating etanercept treatment for ankylosing spondylitis (AS) or psoriatic arthritis (PSA) in germany: a real-world analysis. Value Health. 2019;22:S432. https://doi.org/10.1016/j.jval.2019.09.185.

    Article  Google Scholar 

  40. Acurcio FDA, Guerra Junior AA, da Silva MRR, Pereira RG, Godman B, Bennie M, et al. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Curr Med Res Opin. 2020;36(4):677–86. https://doi.org/10.1080/03007995.2020.1722945.

    Article  PubMed  Google Scholar 

  41. Starr M, Keystone E, Faraawi R, Bessette L, Haraoui B, Olszynski W, et al. Predictors of treatment retention among patients with rheumatoid arthritis or ankylosing spondylitis treated with remicade® (infliximab) for long-term in canadian real-world. Arthritis Rheumatol. 2016;68:945–7. https://doi.org/10.1002/art.39977.

    Article  Google Scholar 

  42. Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M et al. Biologic treatment registry across Canada (BioTRAC): A multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open. 2016;6(4). https://doi.org/10.1136/bmjopen-2015-009661.

  43. Gendelman O, Weitzman D, Rosenberg V, Shalev V, Chodick G, Amital H. Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. Br J Clin Pharmacol. 2018;84(4):786–95. https://doi.org/10.1111/bcp.13494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Armagan B, Sari A, Erden A, Kilic L, Guven DC, Pashayev T, et al. Ankylosing spondylitis patients with uveitis had better adalimumab retention rate: Hur-bio real life results. Ann Rheum Dis. 2017;76:1300–1. https://doi.org/10.1136/annrheumdis-2017-eular.4367.

    Article  Google Scholar 

  45. Si B, Rotar Z, Tomsic M. The persistence of golimumab in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: analysis of prospectively collected data in the Slovenian national online registry of patients treated with biologics. Value Health. 2016;19(3):A228.

    Article  Google Scholar 

  46. Grosso V, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, et al. Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry. Ann Rheum Dis. 2015;74:280. https://doi.org/10.1136/annrheumdis-2015-eular.3336.

    Article  Google Scholar 

  47. Di Giuseppe D, Frisell T, Askling J. Effectiveness and persistence of golimumab across rheumatic disease indications in clinical practice: results from the national Swedish register. Ann Rheum Dis. 2016;75:411–2. https://doi.org/10.1136/annrheumdis-2016-eular.1768.

    Article  Google Scholar 

  48. Belhassen M, Hudry C, Woronoff M, Levy Bachelot L, Deschamps C, Ginoux M, et al. Treatment persistence with golimumab in France. Value Health. 2016;19(7):A592.

    Article  Google Scholar 

  49. Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi-Puttini P, et al. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry. Clin Exp Rheumatol. 2017;35(5):804–9.

    PubMed  Google Scholar 

  50. Serrano-Benavente B, González Fernández CM, Valor L, Nieto-González JC, González-Benítez RD, Janta I et al. Golimumab retention rate in patients with spondyloarthritis. differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2018;77:1001. https://doi.org/10.1136/annrheumdis-2018-eular.4135.

  51. Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: Non-interventional GO-NICE study in Germany. BMJ Open. 2018;8(6). https://doi.org/10.1136/bmjopen-2017-021082.

  52. Rotar Z, Tomsic M, Praprotnik S. The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clin Rheumatol. 2019;38(2):297–305. https://doi.org/10.1007/s10067-018-4324-7.

  53. Dackhammar C, Forsblad-D'Elia H, Kristensen LE, Lindström U, Ernestam S, Jacobsson L. Survival on drug in patients with spondyloarthritis receiving certolizumab pegol. Results from the nationwide Swedish rheumatology quality register. Ann Rheum Dis. 2015;74:266. https://doi.org/10.1136/annrheumdis-2015-eular.3787.

  54. Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014;7(2):71–81.

    PubMed  PubMed Central  Google Scholar 

  55. de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis. 2007;66(1):133–4. https://doi.org/10.1136/ard.2006.057745.

    Article  PubMed  PubMed Central  Google Scholar 

  56. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66(9):1252–4. https://doi.org/10.1136/ard.2007.072397.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

    Chia-Ling Yu

  2. Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

    Chung-Han Yang

  3. Department of Dermatology, Chang Gung Memorial Hospital, Linkou, 5, Fuxing St, Guishan Dist, Taoyuan, 33305, Taiwan

    Ching-Chi Chi

  4. College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Ching-Chi Chi

Authors
  1. Chia-Ling Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chung-Han Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ching-Chi Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CLY: conceptualization, data acquisition, writing, reviewing, artwork preparation and editing; CHY: writing, reviewing and validation; CCC: supervision, conceptualization, validation, writing, original draft preparation, reviewing, and editing.

Corresponding author

Correspondence to Ching-Chi Chi.

Ethics declarations

Competing interests

CLY and CCC declare that they have no competing interests. CHY received speaking fees from Chugai Pharma Taiwan, AbbVie Taiwan, Taiwan Tanabe Seiyaku, UCB Taiwan, Novartis Taiwan, and Pfizer Taiwan.

Code availability

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All the papers included in this systematic review and meta-analysis have been fully referenced.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 1503 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, CL., Yang, CH. & Chi, CC. Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence. BioDrugs 34, 669–679 (2020). https://doi.org/10.1007/s40259-020-00442-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-020-00442-x

Search

Navigation